Victoza liraglutide: Additional Phase III data

Novo Nordisk A/S (CSE:NVO; NYSE:NVO), Bagsvaerd, Denmark
Product: Victoza liraglutide ( NN2211)
Business: Endocrine/Metabolic
Molecular target: Glucagon-like peptide-1 receptor (GLP-1R) (GLP1R)
Description: Long-acting analog of

Read the full 250 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE